Signed in as:
filler@godaddy.com
Search, Find and Analyze with Precision
Far better than Boolean text searching: IPV Patent Analysis reports use generative AI, large language models and proprietary scoring algorithms to compare a Subject patent to potentially thousands of other patents within a defined CPC family. CPC stands for Cooperative Patent Classification (CPC) which is a hierarchical classification system that’s managed by the EPO and the US Patent and Trademark Office. It’s divided into nine sections which in turn are sub-divided into classes, sub-classes, groups and sub-groups. There are approximately 250,000 classification entries.
Precision Results: IPV Patent analysis reports deliver precise comparisons that identify similar patents, score them and then clearly reveal in an easy-to-read report what sets the Subject patent apart from others in its CPC family. It also suggests the probability of anticipated direct or indirect infringement based on the analysis of claims. Once similar patents within a CPC have been identified, users have access to an interactive dashboard enabling them to drill down and gain the insights they need to power smart decisions when developing a product strategy or when negotiating and building patent portfolios. These highly customizable dashboards bring together data from a wide variety of sources to reveal key factors like recent office actions, assignees, jurisdictions and a lot more. This provides an easy way to connect to virtually all publicly available data including litigation reports, bringing all of this information to the user in a form that's fast and easy to digest and act upon.
Molecular Biology Example
Report for the Subject file: WO2025012350A1.pdf
Report for the Subject file: WO2025012350A1.pdf
Title: Rna containing modified nucleosides and methods of use
Date range filter: After: 2018-01-01 Before: 2025-01-28 CPCs Used: C12N15/11, C12N15/11, C12N15/11, A61K48/00, C12N15/11, A61K48/00
Number of Top Patents for Claims Breakdown: 150
Inventor: Katalin Kariko, Drew Weissman
Filing Date: 2007-03-01
Priority Date: Priority to EP19168984.3A 2006-08-21
Publication Date: 2007-03-01
- Overall, the patent provides a detailed framework for overcoming two major obstacles in RNA-based therapeutics—the innate immunogenicity of exogenous RNA and the often suboptimal translation efficiency—thereby facilitating the development of effective RNA therapies for a broad range of medical conditions.
- Modified RNA Composition: The invention provides RNA molecules that are synthesized to include modified nucleosides—most notably pseudouridine but also other modifications such as m5C, m5U, m6A, S2U, and 2′‑O‑methyl‑U.
- Reduction of Immunogenicity: A key advantage of the modified RNA molecules is their reduced capacity to trigger the innate immune response.
- Enhanced Translation Efficiency: The modified RNA not only shows lower immunogenicity but also exhibits enhanced translation.
- Methods of Synthesis: The patent describes protocols for in vitro transcription using phage RNA polymerases (T7, SP6, or T3) in which one or more of the standard ribonucleoside triphosphates is replaced by a corresponding modified nucleotide triphosphate. This method reliably yields RNA molecules with the desired modifications without affecting the integrity of the transcript.
- Delivery and Therapeutic Applications: In addition to synthesis, the patent outlines formulations (including complexation with lipid-based transfection reagents or encapsulation in nanoparticles) for delivering the modified RNA into cells and tissues.
- Broad Claims: The claims of the patent cover the compositions (modified mRNA, oligoribonucleotides, gene-therapy vectors) as well as methods of reducing RNA immunogenicity and enhancing its translation. They also extend to specific therapeutic methods such as inducing protein production in target cells, treating various diseases by administering the modified RNA, and optimizing RNA stability and expression profiles in vivo.
- Accession: WO2007024708A2 patent document contains a reference to an "accession" related to the nucleotide sequence associated with human TLR3. Specifically, the document mentions the accession number NM_003265 for a gene segment involved in the experimental details. The accession is connected to a sequence encoding shRNA with 20-nt-long homology to human TLR3
---------------------------------------------------------------------------------Subject Description Overview:
The Subject invention focuses on a vector for use in the treatment and/or prevention of PRRSV infection, utilizing a viral expression cassette that includes a cDNA of an attenuated PRRSV virus genome operably linked to a promoter. The primary function is to provide a medicament, specifically a vaccine, that effectively prevents or treats PRRSV infection in pigs. The underlying functions involve the administration of the vector to induce an immune response against PRRSV, with the vector designed to be safe and effective, as evidenced by the absence of increased rectal temperature post-challenge and reduced clinical symptoms and viremia compared to existing vaccines..
Top Scoring Comparisons
Compared Patents # 1 of 470
Compared file: US9981033B2
PRRSV minor protein-containing recombinant viral vectors and methods of making and use thereof
Inventor: MEBATSION TESHOME
Assignee: MERIAL INC
Priority Date: 06-23-2015
Publication Date: 05-29-2018
CPC: A61K39/12
IPV™ Rating: 6.9928
Inferred Equivalence: Medium
Lens: https://www.lens.org/lens/patent/101-699-161-310-581/frontpage?l=en
____________________________________________________________
Primary Function:
The primary function of the Compared invention is to provide a safe and effective immunological or vaccine composition against Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) using recombinant viral vectors, specifically adenovirus 5 (Ad5) vectors, to express PRRSV antigens such as gp2, gp3, gp4, and E. This composition aims to induce a broad immunity, including humoral, cellular, and mucosal responses, and is designed to be compatible with the DIVA strategy, allowing differentiation between infected and vaccinated animals.
---------------------------------------------------------------------------------
Summary of Analysis:
There is an overall moderate possibility of overlap between the 'Subject' and 'Compared' claims, primarily due to the shared focus on using vectors for PRRSV vaccination. However, the detailed molecular and chemical constituents and processes differ significantly. The 'Subject' claims emphasize the structure of the vector, including the use of a cDNA of an attenuated RNA virus genome and specific administration methods, while the 'Compared' claims focus on specific PRRSV antigens and the use of different recombinant vectors. This distinction in molecular details suggests that while there is a thematic overlap, the specific implementations and technologies used in each set of claims are distinct, leading to a moderate level of anticipated overlap in the patent context.
---------------------------------------------------------------------------------Description Overview:
The core concept of the Compared invention involves the use of recombinant adenovirus vectors to deliver and express specific PRRSV antigens. The functional principles include the systemic delivery of the vector to the host, where the viral expression cassette within the vector, containing the cDNA encoding PRRSV antigens, is operably linked to a promoter to facilitate expression. The underlying functions involve the induction of an immune response through the expression of these antigens, which are essential components for triggering both humoral and cellular immunity. The core interactions occur between the expressed antigens and the host's immune system, leading to the production of antibodies and activation of T-cells. Internally, the dynamics involve the transcription and translation of the antigen-encoding genes within the host cells, leading to the presentation of antigens on the cell surface for immune recognition. No specific molecular or chemical constituents are detailed beyond the use of adenovirus vectors and PRRSV antigens, and no Genbank or Accession numbers are provided.
---------------------------------------------------------------------------------Asserted Novelty and Innovation:
The Subject invention introduces novelty through the use of an attenuated PRRSV genome within the vector, which has demonstrated effectiveness in preventing PRRSV infection without causing adverse effects such as increased rectal temperature post-challenge. This contrasts with the Compared invention, which uses recombinant adenovirus vectors to express specific PRRSV antigens. The Subject invention's approach of using the entire attenuated genome rather than specific antigens may provide broader immunity and potentially more effective protection against various PRRSV strains. The overlap between the two inventions lies in their aim to combat PRRSV infection through vaccination, but the Subject invention's use of an attenuated whole genome vector represents a distinct approach from the antigen-specific recombinant vector strategy of the Compared invention. Molecularly, the Subject invention involves the entire attenuated PRRSV genome, while the Compared invention focuses on specific PRRSV antigens, indicating a significant difference in their molecular constituents and processes.
---------------------------------------------------------------------------------Similarities Analysis:
The claims from 'Subject' and 'Compared' both focus on vectors used in the context of vaccines or immunological compositions targeting Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), which is a member of the Arteriviridae family. The 'Subject' claims describe a vector comprising a viral expression cassette with a cDNA of an attenuated RNA virus genome, specifically mentioning PRRSV in several claims. The 'Compared' claims detail a composition with recombinant viral vectors encoding specific PRRSV antigens (gp2, gp3, gp4, and E). Both sets of claims mention the use of vectors for vaccination or treatment against PRRSV, indicating a thematic overlap. However, the 'Subject' claims focus more on the structure and administration of the vector, while the 'Compared' claims emphasize specific antigen sequences and the use of different types of vectors like adenovirus, baculovirus, and others. There is a notable semantic similarity in the use of vectors for PRRSV, but the molecular details and specific constituents differ significantly between the two sets of claims.
---------------------------------------------------------------------------------Overlap Analysis:
The overlap between the 'Subject' and 'Compared' claims is primarily thematic, centered around the use of vectors for PRRSV vaccination. The 'Subject' claims describe a broader approach to vector design and administration, including the use of a bacterial artificial chromosome (BAC) and an inducible bacterial origin of replication, which are not mentioned in the 'Compared' claims. Conversely, the 'Compared' claims focus on specific PRRSV antigens and the use of various recombinant vectors, which are not detailed in the 'Subject' claims. While there is a thematic overlap in the use of vectors for PRRSV, the molecular and chemical constituents and processes described are distinct, leading to a moderate level of overlap.
---------------------------------------------------------------------------------Sequence Data:
Sequence Count: 139
Sequence Types: P, N
Organisms: 'Porcine reproductive and respiratory syndrome virus', 'PRRSV VR2332', 'Unknown/Artificial'
Bucket: NT_1_100, AA_51_300, NT_5001_100000, AA_1_50, NT_101_5000
---------------------------------------------------------------------------------
Claims Breakdown and Comparison Summary:
Compared Patent (US9981033B2) Claim number: 1 and Subject Claim: 14
Both claims focus on compositions for use as vaccines or immunological agents against PRRSV. The Compared claim specifies the use of recombinant viral vectors encoding specific PRRSV antigens (gp2, gp3, gp4, and E), while the Subject claim describes a broader approach with a vector containing an attenuated RNA virus genome from the Arteriviridae family. The scope of the Compared claim is narrower, focusing on specific antigens, whereas the Subject claim's scope is broader, encompassing any attenuated RNA virus from the Arteriviridae family. The similarity lies in their use as vaccines, but the Subject claim's approach is more general and could potentially include the specific antigens mentioned in the Compared claim.
---------------------------------------------------------------------------------
Compared Patent (US9981033B2) Claim number: 2 and Subject Claim: 14
Both claims describe pharmaceutical compositions that include a vector and a carrier, intended for use as vaccines. The Compared claim specifies the use of specific types of recombinant vectors (Ad5-PRRSV, baculovirus, porcine cytomegalovirus, or poxvirus vectors), while the Subject claim is more general, mentioning a vector with an attenuated RNA virus genome from the Arteriviridae family. The scope of the Compared claim is narrower due to the specific vector types, whereas the Subject claim's scope is broader, potentially encompassing the vectors mentioned in the Compared claim. The similarity is in their use as vaccines and the inclusion of a carrier, but the Subject claim's approach is more general.
Compared Patents # 2 of 470
Publication # US20230129061A1
Compared file: EP3313864B1
PRRSV MINOR PROTEIN-CONTAINING RECOMBINANT VIRAL VECTORS AND METHODS OF MAKING AND USE THEREOF
Inventor: MEBATSION TESHOME
Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC
Priority Date: 06-23-2015
Publication Date: 07-28-2021
CPC: C07K14/08
IPV™ Rating: 6.9589
Inferred Equivalence: Medium
Lens: https://www.lens.org/lens/patent/129-303-468-794-616/frontpage?l=en
____________________________________________________________
Primary Function:
The primary function of the Compared invention is to provide a safe and effective immunological or vaccine composition for eliciting a protective immune response against Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in animals, particularly pigs. This is achieved through the use of one or more recombinant viral vectors that express multiple PRRSV antigens from a single vector, aiming to induce both humoral and cell-mediated immune responses.
---------------------------------------------------------------------------------Summary of Analysis:
There is an overall moderate possibility of overlap between the 'Subject' and 'Compared' patents, primarily due to the shared focus on using vectors for PRRSV vaccine development. However, the specific molecular and chemical constituents and processes described in the claims differ significantly. 'Subject' claims utilize a broader approach with a cDNA of an attenuated RNA virus genome and a bacterial artificial chromosome, while 'Compared' claims are more specific, focusing on recombinant Ad5-PRRSV vectors expressing multiple PRRSV antigens with high sequence identity to specified sequences. The detailed methodologies and components, such as the use of BACs and specific antigen expression, indicate distinct approaches to achieving the same goal of PRRSV vaccine development. Therefore, while there is some overlap in the general context, the detailed molecular and chemical processes suggest a low possibility of significant overlap in the patent claims.
---------------------------------------------------------------------------------Description Overview:
The Compared invention utilizes recombinant Ad5-PRRSV vectors to express PRRSV antigens such as gp2, gp3, gp4, and E, and optionally gp5a and gp5. These vectors contain heterologous polynucleotides encoding these antigens, which are operably linked to promoter elements and optionally enhancers to facilitate expression. The systemic principle involves the administration of these vectors to induce an immune response, with the antigens being processed and presented to the immune system to trigger specific immune responses. The foundational process includes the transcription and translation of the viral antigens within the host cells, leading to the production of viral proteins that stimulate the immune system. Essential components include the Ad5 vector, the PRRSV antigen-encoding polynucleotides, and the pharmaceutically or veterinarily acceptable carrier. Core interactions involve the interaction of the expressed antigens with the host's immune cells, leading to the activation of B and T cells. Internal dynamics include the cellular uptake of the vector, antigen processing, and the subsequent immune response cascade. The molecular and chemical constituents primarily involve the nucleic acids (DNA) encoding the antigens and the proteins produced from these sequences. No specific Genbank or Accession number is mentioned in the patent.
---------------------------------------------------------------------------------Asserted Novelty and Innovation:
The Subject invention introduces novelty through the use of an attenuated RNA virus genome from the Arteriviridae family, specifically designed to be used in a vaccine composition. This differs from the Compared invention, which uses recombinant Ad5 vectors expressing multiple PRRSV antigens. The Subject invention focuses on the use of a single attenuated virus genome, potentially offering a broader immune response due to the inclusion of the entire viral genome, whereas the Compared invention targets specific antigens. The overlap between the two inventions lies in their aim to combat PRRSV, but the molecular and chemical constituents differ significantly; the Subject uses an attenuated viral genome, while the Compared uses specific antigen-encoding polynucleotides. The Subject's approach may provide a more comprehensive immune response, potentially reducing the risk of viral shedding and increasing the effectiveness against various PRRSV strains compared to the targeted antigen approach of the Compared invention.
---------------------------------------------------------------------------------Similarities Analysis:
The claims from 'Subject' and 'Compared' show similarities in the context of using vectors for vaccine development against PRRSV, a virus from the Arteriviridae family. Both sets of claims mention the use of vectors for the treatment or prevention of PRRSV infections, specifically targeting pigs. 'Subject' claims focus on a vector comprising a cDNA of an attenuated RNA virus genome, operably linked to a promoter, and specify the use of a bacterial artificial chromosome (BAC) and an inducible bacterial origin of replication. In contrast, 'Compared' claims detail the use of recombinant viral vectors, specifically Ad5-PRRSV vectors, expressing multiple PRRSV antigens (gp2, gp3, gp4, E, and optionally gp5a/gp5) from a single vector, with a focus on sequence identity to specific SEQ ID NOs. Both sets of claims mention the administration of the vector to subjects, with 'Subject' specifying various administration routes and dosages, while 'Compared' focuses on eliciting a protective response through different administration methods and a prime-boost strategy. The molecular and chemical constituents overlap in the use of viral vectors and the targeting of PRRSV antigens, but the specific approaches and detailed components differ significantly.
---------------------------------------------------------------------------------Overlap Analysis:
The overlap between the claims of 'Subject' and 'Compared' is primarily in the use of vectors for PRRSV vaccine development. 'Subject' claims describe a broader approach using a cDNA of an attenuated RNA virus genome, while 'Compared' claims are more specific, focusing on recombinant Ad5-PRRSV vectors expressing multiple PRRSV antigens with high sequence identity to specified sequences. The overlap in molecular constituents is in the use of viral vectors and targeting PRRSV, but the detailed molecular and chemical processes, such as the use of BACs and specific antigen expression, differ. The overlap in context is moderate, as both aim at PRRSV vaccine development but use different methodologies and components.
---------------------------------------------------------------------------------
Claims Breakdown and Comparison Summary:
Compared Patent (EP3313864B1) Claim number: 1 and Subject Claim: 6
The compared claim focuses on a specific recombinant Ad5-PRRSV vector encoding a PRRSV E antigen with high sequence identity to specified sequences, aimed at eliciting an immune response. The subject claim, on the other hand, describes a vector for use in treating or preventing PRRSV infection, which includes a broader viral expression cassette with an attenuated PRRSV genome. Both claims target PRRSV, but the compared claim is more specific to the E antigen and its sequence identity, while the subject claim is more general in its approach to PRRSV treatment/prevention. The scope of the compared claim is narrower, focusing on a particular antigen and its sequence, whereas the subject claim's scope is broader, encompassing any attenuated PRRSV genome for treatment/prevention.
---------------------------------------------------------------------------------
Compared Patent (EP3313864B1) Claim number: 3 and Subject Claim: 6
The compared claim specifies a recombinant Ad5-PRRSV vector encoding a PRRSV gp2 antigen with high sequence identity to specified sequences, aimed at eliciting an immune response. The subject claim describes a vector for use in treating or preventing PRRSV infection, which includes a broader viral expression cassette with an attenuated PRRSV genome. Both claims target PRRSV, but the compared claim is more specific to the gp2 antigen and its sequence identity, while the subject claim is more general in its approach to PRRSV treatment/prevention. The scope of the compared claim is narrower, focusing on a particular antigen and its sequence, whereas the subject claim's scope is broader, encompassing any attenuated PRRSV genome for treatment/prevention.
---------------------------------------------------------------------------------
Compared Patent (EP3313864B1) Claim number: 4 and Subject Claim: 14
The compared claim describes a specific immunological or vaccine composition that includes recombinant viral vectors expressing multiple PRRSV antigens (gp2, gp3, gp4, E, and optionally gp5a/gp5) from a single vector, along with a carrier. The subject claim outlines a pharmaceutical composition with a vector containing an attenuated RNA virus genome from the Arteriviridae family, also intended as a vaccine. Both claims focus on compositions for vaccination against PRRSV, but the compared claim is more detailed in specifying the antigens and their expression from a single vector, while the subject claim is broader, focusing on the viral genome and its attenuation. The scope of the compared claim is narrower, targeting specific antigens, whereas the subject claim's scope is broader, encompassing any attenuated Arteriviridae virus genome.
---------------------------------------------------------------------------------
Compared Patent (EP3313864B1) Claim number: 5 and Subject Claim: 6
The compared claim details a specific recombinant Ad5-PRRSV vector expressing multiple PRRSV antigens for use in eliciting a protective response against PRRSV, with detailed administration methods and options for prime-boost vaccination. The subject claim describes a vector for use in treating or preventing PRRSV infection, which includes a broader viral expression cassette with an attenuated PRRSV genome. Both claims target PRRSV, but the compared claim is more specific in its antigen expression and administration methods, while the subject claim is more general in its approach to PRRSV treatment/prevention. The scope of the compared claim is narrower, focusing on specific antigens and detailed administration methods, whereas the subject claim's scope is broader, encompassing any attenuated PRRSV genome for treatment/prevention.
Legal Disclaimer: The reports provided herein are machine generated and are intended solely for informational purposes. No representation or warranty is made, either express or implied, regarding the accuracy, completeness, or reliability of the information contained in these reports. Recipients should not rely exclusively on this information for any legal, financial, or professional decision-making and are advised to independently verify its content. Reliance on this material is strictly at the user’s own risk.
Legal Disclaimer: The reports provided herein are machine generated and are intended solely for informational purposes. No representation or warranty is made, either express or implied, regarding the accuracy, completeness, or reliability of the information contained in these reports. Recipients should not rely exclusively on this information for any legal, financial, or professional decision-making and are advised to independently verify its content. Reliance on this material is strictly at the user’s own risk.
